Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, ...

Repligen’s strong growth and bioprocessing expansion position it for success. Find out why RGEN stock is a Buy, with a $175 ...

Equities researchers at Evercore ISI started coverage on shares of Repligen (NASDAQ:RGEN – Get Free Report) in a report ...

Proficio Capital Partners LLC purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) in the fourth ...

Learn more about whether Repligen Corporation or Bio-Techne Corporation is a better investment based on AAII's A+ Investor ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $181.67, a high estimate of $205.00, and a low estimate of $155.00. Highlighting a 7.12% decrease, the ...

Fintel reports that on March 18, 2025, Evercore ISI Group initiated coverage of Repligen (NasdaqGS:RGEN) with a In-Line ...

Evercore ISI initiated coverage of Repligen (RGEN) with an In Line rating and $155 price target The firm sees the company as a high quality ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

In the 10-K report, under ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS, ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug ...